Fangda Partners > Hong Kong, Hong Kong > Firm Profile

Fangda Partners
26/F, One Exchange Square
8 CONNAUGHT PLACE, CENTRAL
HONG KONG
Hong Kong

Hong Kong > Projects and energy Tier 2

Benefiting from significant resources in mainland China, the Hong Kong team at Shanghai-headquartered firm Fangda Partners is particularly well-positioned to advise China-based investors seeking to develop infrastructure and power projects as part of the Belt & Road Initiative. Michael Tam has vast experience across a range of energy, infrastructure and power projects throughout Asia and leads an ‘impressive‘ team that also includes Joe Biqing Zhou, a specialist in cross-border M&A, infrastructure and energy outbound investments.

Practice head(s):

Other key lawyers:

Key clients

Shenzhen Energy Group

China Merchants Group

The Airport Authority Hong Kong

CRRC Corporation Limited

CTHG Fund

Yanchang Petroleum Group (Hong Kong) Co., Ltd.

China Merchants Port Holdings Company Limited

China-Africa Development Fund

International Djibouti Industrial Parks Operation FZCO

Hongkong Electric (Natural Gas) Limited

Veolia

China Harbour Engineering Company Ltd.

CGN Capital Partners Infrastructure Fund III L.P.

State Grid Corporation of China

Taihu Holding and Greenland Group

Beijing Urban Construction Group

HOPU Fund Management Company Limited

Shanghai Electric

Work highlights

  • Advised Shenzhen Energy Group on the development, financing, construction and operation of the 180MW Ramu II Hydropower Plant in Papua New Guinea.
  • Advised a China Merchants Group entity on the redevelopment of a historical port in Djibouti into the East Africa International Special Business Zone.
  • Advised on the financing, construction, development and operation of a deep-water port terminal and related development in Myanmar.

Hong Kong > Capital markets (equity) Tier 4

With a sizeable presence in Hong Kong and the PRC, Fangda Partners has excellent credibility among regional and international issuers and underwriters listing on the Hong Kong stock exchange. Under the guidance of Colin Law, who has 'strong professional skills', the team has been particularly prolific advising on mid-to-high end mandates, including IPOs and H-share offerings, in the healthcare and education sectors.

Practice head(s):

Testimonials

Colin Law has strong professional skills, can respond to various consulting questions of the company in a timely manner, and has a scholarly demeanor.’

Key clients

JW (Cayman) Therapeutics Co. Ltd

Goldman Sachs

J.P. Morgan

Huatai Securities

Morgan Stanley

Southwest Securities (HK) Capital Limited

Agricultural Bank of China Limited

Jinxin Fertility Group Limited

Shandong Fengxiang Co., Ltd.

WuXi Biologics (Cayman) Inc.

WuXi Biologics Holdings Limited

Ant Group Co., Ltd.

Cheshi Holdings Limited

Haina Intelligent Equipment International Holdings Limited

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.

C-MER Eye Care Holdings Limited

Shandong International Trust Co., Ltd.

Bawang International (Group) Holding Limited

G-Resources Group Limited

IDG Corporation

Dialog Group Berhad

Dialog Corporate Sdn Bhd

CDH Investment

CITIC Private Equity

Work highlights

    Hong Kong > Corporate (including M&A) Tier 4

    In addition to its local office, Chinese firm Fangda Partners leverages a presence in Beijing, Shenzhen, Shanghai and Guangzhou, counting its combined knowledge of both PRC and Hong Kong law as one of its key points of differentiation. A further distinguisher is the group’s in-depth sector knowledge which encompasses TMT, logistics, life sciences, healthcare and education. The team is praised for its ‘ability to mobilise resources and the delivery of fast and thoughtful service‘. Practice head Colin Law focuses on international public offerings, public company takeovers, privatisation and regulatory matters; he is supported at partner-level by Norman Zhong, a lawyer with significant M&A, private equity and outbound investment capabilities.

    Practice head(s):

    Other key lawyers:

    Testimonials

    ‘The team provides a great example of smart collective and coordinated work, the client feels understood and proactively supported, things are fluid and simple. Impressive reactivity. Individuals are all available and pleasant to work with.’

    ‘Colin Law has extensive knowledge of the regional markets and practice, provides most adequate advice on deals structuring and negotiations, comes across superbly with the M&A and finance teams, is accessible, fully available and very pleasant to work with.’

    Team members, especially the leading lawyers, have rich M&A experience.

    Colin Law has extensive experience in M&A, which is not only reflected in his knowledge on relevant legal provisions, but also in his judgement and control of project situations. He has excellent communication and coordination skills, understands the demands of all parties, and properly balance the interests of all parties in the given solution, thus effectively promoting the progress of the project.

    Colin Law has extensive experience in M&A especially transactions under the takeovers code. He is one of the preferred lawyers.

    The team is able to operate well both in Mainland China and Hong Kong capital markets, especially in the service of M&A transactions of Chinese listed companies in Hong Kong, and understands Mainland capital market, regulatory requirements as well as Hong Kong capital market requirements, so as to provide excellent “one-stop” solutions for clients. They also offer a package of competitive fees of Mainland + Hong Kong.

    Fangda Law Firm has excellent strength in Mainland China. In recent years, it has also increased personnel investment in Hong Kong capital market, further enhancing the comprehensive strength of Fangda Mainland and Hong Kong‘.

    Key clients

    Moonton Technology

    Haier Electronics Group Co., Ltd.

    TCL Technology Group Co., Ltd.

    EF Education First

    ASM Pacific Technology Limited

    Sunny Sea Global Limited

    Shanghai Wanye Enterprises

    Ever Harmonic Global Limited

    Brilliance International Holding Limited, Golden Fair (Holding) Limited

    Jinxin Fertility Group Limited

    Huadian Fuxin Energy Corporation Limited

    Suez (Asia) Limited

    Work highlights

    • Advised Moonton Technology on its acquisition by ByteDance, one of the largest and most influential deals in the video games industry history.
    • Advised Haier Electronics Group Co., Ltd. (1169.HK) on its privatisation by way of a scheme of arrangement, which is the largest privatisation transaction of a Hong Kong-listed company in 2020.
    • Advised TCL Technology Group Co., Ltd. and its subsidiary in its strategic acquisition of Samsung’s 8.5th generation LCD production line in Suzhou.

    Hong Kong > Dispute resolution: international arbitration Tier 4

    Fangda Partners‘ standalone Hong Kong international arbitration practice has a breadth of experience in commercial and investment disputes and is complemented by the firm’s strong PRC team. Peter Yuen, whose arbitration expertise covers both institutional (mainly, ICC, SCC, LCIA and HKIAC) and ad hoc (mainly UNCITRAL) arbitrations in both English and Chinese, leads the 15-strong team which includes Olga Boltenko, who is noted for investor-state disputes; Andrew Skudder who focuses on commercial and antitrust arbitration; and Matthew Townsend who counts energy sector disputes among his areas of focus.

    Practice head(s):

    Peter Yuen

    Hong Kong > Private equity Tier 4

    With a number of offices in mainland China, Fangda Partners is well placed to handle work in the Greater China market and is well regarded for public company transactions led out of its Hong Kong office. It advises on a number of large private equity and venture capital financing transactions under the leadership of Colin Law.

    Practice head(s):

    Other key lawyers:

    Wei Chen (Hong Kong/Beijing)

    Key clients

    PAG

    Nayuki

    Hillhouse Capital

    Alibaba

    Aspex Master Fund

    IDG Capital

    Softbank Vision Fund

    OrbiMed Partners

    CICC Culture Consumption Industry Equity Investment Fund (Xiamen) Partnership (Limited Partnership)

    Work highlights

    • Advised PAG on its pre-IPO investment in China Youran Dairy Group Limited.
    • Advised Alibaba and Aspex Master Fund in the pre-IPO investments of Xpeng, one of China’s leading smart electric vehicle companies.
    • Advised IDG Capital as a lead investor in its participation in the Series B financing of Voyager Group Inc., being the autonomous vehicles development arm of Didi group.

    China > Investment funds: PRC firms

    Fangda Partners is highly active in the investment fund space, advising on the full lifecycle of funds from formation and structuring through to closings. The team handles matters involving specialist funds such as funds-of-funds and funds-of-one. In addition to acting for Chinese clients, the practice assists international clients in entering the Chinese market through the Qualified Domestic Limited Partner program. Richard Guo acts for a range of fund sponsors in complex matters such as GP-led fund restructurings; elsewhere, Zhen Chen has experience across a range of fund types including angel, venture capital, and private equity funds. Flora Qian and Candy Tang are also key contacts in the practice; Qian specialises in private equity and acts for a number of prominent US sponsors.

    Practice head(s):

    Other key lawyers:

    Testimonials

    ‘As one of the first legal service teams to get involved in renminbi private equity funds, they have many years’ experience of serving well known Chinese and international PE funds. They offer a comprehensive range of services and have very solid capabilities in terms of both legal theory and business practice. The partners have an excellent legal skills and a wealth of experience of localisation, as well as a deep understanding of the complex business practices of the industry, enabling them to provide clients with realistic and workable legal solutions.’

    ‘Richard Guo has a wealth of experience of serving both international and Chinese private equity funds, as well as a high level of familiarity with the situation in China, as well as an incisive understanding of the laws and practical development of renminbi private equity funds, an area in which he is one of the key industry figures. Zhen Chen has excellent knowledge of legal theory and technique, and is able to provide clients with perfect legal solutions. Flora Qian is able to maintain good relationships and levels of interaction with clients, and provide realistic, workable legal solutions.’

    Key clients

    Primavera Capital

    Jinyi Capital

    Everbright Group

    China Cheng Tong Holdings Group Ltd.

    GGV Capital

    Power Corporation of Canada

    Taikang Qianheng Fund-of-funds

    Oaktree Capital

    AEW Capital

    Starbucks

    APlus Partners

    PAG

    Vision Knight Capital

    China Manufacturing Transformation and Upgrading Fund

    Boyu Capital

    Buhuo Venture Capital

    Work highlights

    • Handled Primavera Capital’s formation of its third RMB flagship fund with a total commitments of RMB3.3 billion, involving parallel funds and other complex structuring considerations.
    • Advised Jinyi Capital on the structuring and formation of its first RMB-denominated private equity fund.
    • Advised Everbright Group on the structuring and formation of a “One Belt One Road” fund with a target size of RMB 10 billion.

    China > Life sciences and healthcare: PRC firms

    Fangda Partners 'always showcases a high level of professionalism and commitment to best-practice'. The 12-partner team has 'an exceptional understanding of the life sciences industry and is able to cover all of the key areas relevant to this field'. In recent work, the group advised on global pharmaceutical companies' merger and antitrust matters, equity financing, Covid-19 vaccine licensing deals, establishing a regulator framework for clinical trials, engaging with NGOs, overseas listings, patent infringement, and government investigations. Its client roster features a large number of multinational pharmaceutical companies and investment funds that specialise in the healthcare sector. Josh Shin and Diana Li focus on M&A transactions; Michael Han handles competition-related matters; Kate Yin is recommended for regulatory compliance; and Fang Qi focuses on IP-related transactions and litigation. They jointly lead the life sciences and healthcare group, which bolstered its regulatory expertise with the hire of Jason Wu who joined from Global Law Office in 2020. Hong Kong-based Vanessa Cheung is also noted for corporate and commercial transactions. Sherry Yao is another key name.

    Other key lawyers:

    Testimonials

    ‘Fangda team always showcases a high level of professionalism and their commitment to best-practice. The team has an exceptional understanding of the life sciences industry and is able to cover all of the key areas relevant to this field. They took the time to understand our products and our company’s comparative advantage, and could perfectly meet our needs.’

    ‘Thoughtful, responsive and professional are the words that come to mind when I think of Josh. Finding someone who always has sight of the bigger picture while diving into the smallest details to ensure the quality of work product is not easy. Josh Shin has distinguished himself for his professionalism, enthusiasm to the career and sensitivity of industry, and I would recommend him to other colleagues without the slightest hesitation.’

    The firm works as a team with a very deep bench serving clients with almost all needs. The quality, thoroughness and responsiveness of the team is extraordinary. Highly recommended for life sciences and healthcare companies.

    The team has very broad exposure to most legal issues for life sciences companies. They are creative in solving difficult issues and stand out for their creative legal solutions.’

    The feedback is timely, the legal opinions are forward-looking, and combine business needs.

    Key clients

    Novartis

    Bayer Healthcare

    AstraZeneca

    Roche China

    Gilead Sciences

    Abbott China

    WuXi AppTech

    Watson Pharmaceuticals

    Mindray Medical

    APBI Holdings

    Danaher Corporate

    Fresenius Kabi

    BioGene

    Hasico Pharmaceutical Group

    Hais Thera Scientific Fund I

    Yunfeng Fund II

    TPG Growth

    Yunfeng Capital

    Sino Medcare

    Roper Technology

    Assembly BioScience

    Edding Pharm

    Everbright Healthcare Fund

    C-Stone Pharmaceutical

    Wuxi NextCode

    Hanhui Pharma

    Shanghai Kehua Bioengineering

    Astellas

    Brooks Automation

    EdiGene Beijing Biotechnology

    LifeTech Scientific Corporation

    Wuxi JW Therapeutics

    C-Bridge Capital

    PPD

    PAG

    DKSH

    CDBI Capital

    Mylan

    Sorrento Therapeutics

    Shiyu Capital

    LYFE Capital

    CICC Healthcare Fund

    CVC Capital

    Centurium Capital

    Hillhouse Capital

    CR-CP Life Science Fund

    Highlight Capital

    Hosen Healthcare Capital

    Haier Healthcare

    Johnson & Johnson

    Straumann

    Anheart Therapeutics

    Smith & Nephew

    MitrAssist

    Visen Pharmaceuticals

    Laekna Therapeutics

    Medela

    Vyaire Medical

    MSD

    Vazyme Biotechnology

    Zai Lab

    CMS (China Medical System)

    Aspen

    Medela

    Work highlights

    • Advised AstraZeneca on a licensing deal with Shenzhen Kangtai Biological Products Co., Ltd., under which AstraZeneca will license the adenovirus vector-based COVID-19 vaccine, AZD1222, to BioKangtai.
    • Acted for Mylan N.V. (Nasdaq: MYL), on its global merger with Upjohn, the off-patent branded and generic established medicine business of Pfizer, creating a new global pharmaceutical company, Viatris.
    • Assisted Visen with establishing the entire set of regulatory systems regarding various aspects of its operation (especially the clinic trials), including code of conduct, internal training, SOPs, regulatory advice, and contract templates.

    Asia Pacific: Regional International Arbitration > Leading firms

    Fangda Partners‘ international arbitration team stands out for greater China disputes and is one of the few Chinese law firms active in complex and high-value arbitrations inside and outside China involving Chinese elements. The group is led in mainland China by Nuo Ji, Benjamin Miao and Daniel Huang in Shanghai and Ming Kang and Helen Shi in Beijing. While in Hong Kong Peter Yuen, Olga Boltenko (who is noted for investor-state disputes) and energy sector expert Matthew Townsend are key contacts.

    Practice head(s):

    Benjamin Miao; Daniel Huang; Nuo Ji; Ming Kang; Helen Shi

    The firm: Founded in 1993, Fangda Partners is a full-service law firm advising on PRC and Hong Kong laws.

    One firm approach
    We have approximately 700 lawyers in our five offices in major Chinese cities: Beijing, Guangzhou, Hong Kong, Shanghai and Shenzhen. We operate as a single, integrated partnership, not as an alliance of lawyers in different locations.

    Our lawyers collaborate seamlessly across practice groups and locations to provide our clients with exceptional service, sophisticated advice and practical solutions founded on our legal expertise, sound knowledge of market practice, deep understanding of the industry landscape and proven ability to assist our clients achieve their business objectives.

    Firm of choice for the most difficult legal issues
    We are the firm of choice for businesses requiring solutions to their most difficult and complex legal issues. Leading companies and financial institutions in China and around the world turn to us for legal representation or counseling on their most significant legal and business challenges, whether transactions or disputes.

    Cross-border capabilities with a China edge
    We are known for our cross-border capabilities with a China edge.Our team consists of lawyers qualified in Australia, England and Wales, Singapore, U.S., Hong Kong and the PRC.

    The diversity of our professionals and our strong local law capabilities enable us to bridge legal, regulatory, language and cultural differences that clients inevitably face in transactions and disputes involving multiple jurisdictions.

    At the forefront of Chinese commercial practice
    We have been at the forefront of the development of commercial law practice in China for over two decades.

    We have a proven track record advising clients on groundbreaking transactions or defending them in unprecedented disputes. Some selected notable matters on which we have advised include:

    • First initial public offering by a Chinese company involving an international underwriter
    • The first domestic listing by a company incorporated outside the PRC (so-called red chip company)
    • Formation of the first open-end mutual fund in China
    • First foreign acquisition of a controlling stake in a Chinese public company
    • First FRAND litigation in China
    • Representing the claimant in obtaining the first injunction in an IP litigation under Chinese procedural law
    • First public interest environmental litigation brought by an NGO against a multinational company in China

    Areas of practice: The firm serves both PRC and international clients in various industries. Practices include,

    • Antitrust/competition
    • Asset-backed securities
    • Banking and finance
    • Capital markets
    • Compliance and government enforcement
    • Dispute resolution
    • Energy and infrastructure
    • Financial institutions
    • General industries
    • Insolvency and restructuring
    • Intellectual property
    • Investment funds
    • Investment management
    • Labor and employment
    • Life sciences and healthcare
    • M&A
    • Private equity
    • Real estate and construction
    • Technology, media and telecommunications
    Number of lawyers in the firm : 570+
    Number of partners in the firm : 170+
    Chinese (Cantonese and Mandarin)
    English
    Finnish
    French
    German
    Japanese